Advertisement

Die Onkologie pp 1815-1846 | Cite as

Myelodysplastische Syndrome

  • A. Ganser

Zusammenfassung

Seit dem ersten publizierten Bericht über therapierefraktäre Anämien unklarer Ätiologie vor mehr als sechzig Jahren (Rhoads u. Barker 1938), waren bis Anfang der achtziger Jahre verschiedene Bezeichnungen für die heutzutage als myelodysplastische Syndrome (MDS) bezeichnete Krankheitsgruppe gebräuchlich: präleukämische Anämie, Präleukämie, hämatopoetische Dysplasie, dysmyelopoetisches Syndrom, refraktäre Anämie, erworbene sideroachrestische Anämie, chronische erythrämische Myelose, Oligoleukämie, oligoblastäre Leukämie, „smoldering“ Leukämie, subakute myeloische Leukämie u. a. Im Jahre 1982 wurde schließlich von der FranzösischAmerikanisch-Britischen (FAB) Arbeitsgruppe derTerminus „myelodysplastische Syndrome“ (MDS) geprägt, der sich seitdem durchgesetzt hat (Bennett et al.1982).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aivado M, Rong A, Stadler M et al. (2002) Favourable resopnse to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a„non-clonal” pattern of X-chromosome inactivation in bone marrow cells. Eur J Haematol 68: 210–216PubMedGoogle Scholar
  2. Aksoy M, Erden S, Dincol G (1976)Typesof leukemia in chronic benzene poisoning:a study in 34 patients.Acta Haematol 55: 65–72Google Scholar
  3. Anderson JE, Anasetti C, Appelbaum FR, Schoch G, Gooley TA, Hansen JA et al. (1996b) Unrelated donor marrow transplantation for myelodysplasia/MDS) and MDS-related acute myeloid leukaemia.BrJ Haematol 93: 59–67Google Scholar
  4. Anderson JE, Appelbaum FR, Fisher LD et al. (1993) Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 82: 677–681PubMedGoogle Scholar
  5. Anderson JE, Appelbaum FR, Schoch G et al. (1996a) Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 14: 220–226PubMedGoogle Scholar
  6. Anderson JE, Appelbaum FR, Schoch G et al. (1996c) Allogeneic bone marrow transplantation for refractory anemia: A comparison of two preparative regimens and analysis of prognostic factors. Blood 87: 51–58PubMedGoogle Scholar
  7. Anderson JE, Gooley TA, Schoch G et aí. (1997) Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 89: 2578–2585PubMedGoogle Scholar
  8. Anderson M, Carstensen B, Visfeldt J (1993) Leukemia and other related hematological disorders among Danish patients exposed to thorotrast. Radiat Res 134: 224–233Google Scholar
  9. Andreeff M, Stone R, Michaeli J et al. (1992) Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood 80: 2604–2609PubMedGoogle Scholar
  10. Aricò M, Biondi A, Pui CH (1997) Juvenile myelomonocytic leukemia. Blood 90: 479–488PubMedGoogle Scholar
  11. Armitage JO (2000) Myelodysplasia and acute leukemia after autologous bone marrow transplantation (editorial). J Clin Oncol 18: 945–946PubMedGoogle Scholar
  12. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S (2003) Treatment-related myelodysplasia and acute leukemia in non-Hodgkin’s lymphoma patients.J Clin Oncol 21: 897–906PubMedGoogle Scholar
  13. Asano H, Ohashi H, Ishihara M (1994) Evidence for nonclonal hematopoietic progenitor cell populations in bone marrow of patients with myelodysplastic syndromes. Blood 84:588–594PubMedGoogle Scholar
  14. Asimakopoulos FR, Green AR (1996) Deletions of chromosome 20q and the pathogenesis of myeloproliferative disorders. Br J Haematol 95: 219–226PubMedGoogle Scholar
  15. Aul C, Gattermann N, Heyll A, Germing U, Derigs G, SchneiderW (1992b) Primary myelodysplastic syndrome:analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 6: 52–59Google Scholar
  16. Aul C, Gattermann N, Schneider W (1992a) Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 82: 358–367PubMedGoogle Scholar
  17. Aul C, Giagounidis A, Germing U, Ganser A (2002) Evaluating the prognosis of patients with myelodysplastic syndromes. Ann Hematol 81: 485–497Google Scholar
  18. Aul C, Runde V, Gattermann N (1993) All-trans retinoic acid in patients with myelodysplastic syndromes: Results of a pilot study. Blood 82: 2967–2974PubMedGoogle Scholar
  19. Aul C, Runde V, Germing U, Burk M, Heyll A, Hildebrandt B, Willers R (1995) Remission rates, survival and prognostic factors in 94 patients with advanced MDS treated with intensive chemotherapy (abstract). Ann Haematol 70 (Suppl II): A138Google Scholar
  20. Aul C, Verbeek W (2002) Myelodysplastische Syndrome. In: Classen M, Dierkesmann R, Heimpel H, Koch KM, Meyer J, Müller OA, Specker C, Theiss W (Hrsg) Rationelle Diagnostik und Therapie in der Inneren Medizin. Urban and Fischer, München, B 7: 1–5Google Scholar
  21. Bagby GC, Gabourel JD, Linman JW (1980) Glucocorticoid therapy in the preleukemic syndrome (hemopoietic dysplasia): identification of the responsive patients using in-vitro techniques. Ann Intern Med 92: 55–58PubMedGoogle Scholar
  22. Baker KS, DeForTE, Burns U, Ramsay NK, Neglia JR Robison LL (2003) New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and riskfactors.J Clin Oncol 21: 1352–1358PubMedGoogle Scholar
  23. Bartram CR (1992) Molecular genetic aspects of myelodysplastic syndromes. Hematol Oncol Clin N Am 6: 557–570Google Scholar
  24. Beaupre DM, Kurzrock R (1999) RAS and Leukemia:from basic mechanisms to gene-directed therapy.J Clin Oncol 17: 1071–1079PubMedGoogle Scholar
  25. Bennett JM, Catovsky D, Daniel MT et al. (1994) The chronic myeloid leukemias:guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronich myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukemia Group. Br J Haematol 87: 746–754PubMedGoogle Scholar
  26. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, SuItan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51: 189–199PubMedGoogle Scholar
  27. Beral V, Fraser P, Carpenter L, Booth M, Brown A, Rose G (1988) Mortality of workers of the atomic weapons establishment 1951–1982. Br Med J 297: 755–770Google Scholar
  28. Beral V, Inskip H, Fraser P, Booth M, Caleman D, Rose G (1985) Mortality of employees of the United Kingdom atomic energy authority 1946–1979. Br Med J 291: 440–447Google Scholar
  29. Beran M, Estey E, O’Brien Set al. (1999) Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 17: 2819–2830PubMedGoogle Scholar
  30. Bernasconi C, Alessandrino EP, Bernasconi Petal. (1998) Randomized clinical study comparing aggressive chemotherapy with or without GCSF support for high risk myelodysplastic or secondary acute myeloid leukaemia evolving from MDS.BrJ Haematol 102: 678–683PubMedGoogle Scholar
  31. Biesma DH, Van den Twee! JG, Verdonck LF (1997) Immunosuppressive therapy for hypoplastic myelodysplastic syndromes.Cancer 79: 1548 1551Google Scholar
  32. Boice JD, Blettner M, Kleinerman RA et al. (1987) Radiation dose and leukemia risk in patients treated for cancer of the cervix.J Nati Cancer Inst 79: 1295–1311Google Scholar
  33. Bollag G, Clapp DW, Shih Set al. (1996) Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 12: 144–148PubMedGoogle Scholar
  34. Boultwood J, Lewis 5, Wainscoat J5 (1994) The 5q-syndrome. Blood 84: 3253–3260PubMedGoogle Scholar
  35. Bowen D, Culligan C, Jowitt S et al. (2003) Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 120: 187–200PubMedGoogle Scholar
  36. Brownson RC, Novotny TE, Perry MC (1993) Cigarette smoking and adult leukemia. Arch Intern Med 153: 469–475PubMedGoogle Scholar
  37. Bynoe AG, Scott CS, Ford Proberts BE (1983) Decreased T helper cells in the myelodysplastic syndromes. Br J Haematol 54: 97–102PubMedGoogle Scholar
  38. Cachia PG, Taylor C, Thompson PW et al. (1994) Non-dysplastic myelodysplasia? Leukemia 8: 677–681PubMedGoogle Scholar
  39. Cambier N, Wattel E, Menot ML, Guerci A, Chomienne C, Fenaux P (1996) Alltrans retinoic acid in adult chronic myelomonocytic leukemia.Results of a pilot study. Leukemia 10: 1164–1167PubMedGoogle Scholar
  40. Carella AM, Dejana A, Lerma E et al. (1996) In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukemia. Br J Haematol 95: 127–130PubMedGoogle Scholar
  41. Cazzola M, Andersen J E, Ganser A, Hellström-Lindberg E (1998) A patient-oriented approach to treatment of myelodysplastic syndromes. Haematologica 83: 910–935PubMedGoogle Scholar
  42. Cazzola M, Invernizzi R, Bergamaschi G et al. (2003) Mitochondria) ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood 101: 1996–2000PubMedGoogle Scholar
  43. Chan G, DiVenuti G, Miller K (2002) Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome. Am J Hematol 71: 166–171PubMedGoogle Scholar
  44. Checkoway H, Pearce N, Crawford-Brown DL, Cragle DL (1988) Radiation doses and cause specific mortality among workers at a nuclear materials fabrication plant. Am J Epidemiol 127: 255–266PubMedGoogle Scholar
  45. Chen H, Sandier DP, Taylor JA, Shore DL, Liu E, Bloomfield CD, Bell DA (1996) Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet 347: 295–297PubMedGoogle Scholar
  46. Cheson BD, Simon R (1987) Low dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years experience. Sem Oncol 14 [Suppl 1]: 126–133Google Scholar
  47. Chitambar CR, Lobnoch JA, Matthaeus WG, Ash C, Rich PS, Anderson T (1991) Evaluation ofcontinous infusion low-dose 5-Azacytidine in the treatment of myelodysplastic syndromes. Am J Hematol 37: 100–104PubMedGoogle Scholar
  48. Creutzig U, Cantu-Rajnoldi A, Ritter J et al. (1987) Myelodysplastic syndromes in childhood: report of 21 patients from Italy and West Germany. Am J Pediatr Hematol Oncol 9: 324–430PubMedGoogle Scholar
  49. Creutzig U, Ritter J, VormoorJ etal. (1996) Myelodysplasia and acute myelogenous leukemia in Down’s syndrome.A report of 40 children of the AML-BFM Study Group. Leukemia 10: 1677–1686PubMedGoogle Scholar
  50. Darby S, Doll R, Gill SK, Smith PG (1987) Long-term mortality after a single treatment course with X-rays in patients with ankylosing spondylitis. Br J Cancer 55: 179–190PubMedGoogle Scholar
  51. Darley RL, Hoy TG, Baines P, Padua RA, Burnett AK (1997) Mutant N-RAS induces erythroid lineage dysplasia in human CD34-cells. J Exp Med 185: 1337–1347PubMedGoogle Scholar
  52. De WitteT (1990) Response to allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome. Br J Haematol 75: 443–444Google Scholar
  53. De Witte T, Muus P, De Pauwet al. (1990b) Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer 66: 881–837Google Scholar
  54. De Witte T, Suciu S, Boogaerts M et al. (1995b) Intensive remission-induction chemotherapy followed by autologous or allogenic stem cell transplantation (SCT) for high risk MDS and AML secondary to MDS (sAML) in patients 60 years. A joint study of the EORTC LCG and the EBMT (abstract). Blood 86 [Suppl 1]: 618aGoogle Scholar
  55. De Witte T, Suciu S, Boogaerts M et al. (2001) Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes ( MDS) and acute myeloid leukemia following MDS. Blood 98: 2326–2331PubMedGoogle Scholar
  56. DeWitte T, Suciu S, Peetermans M et al. (1995a) Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration.A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer ( EORTC-LCG ). Leukemia 9: 1805–1811Google Scholar
  57. De Witte T, Van Biezen A, Hermans J et al. (1997) Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantion. Blood 90: 3853–3857PubMedGoogle Scholar
  58. De Witte T, Zwaan F, Hermans J et al. (1990a) Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group ( EBMTG ). Br J Haematol 74: 151–155PubMedGoogle Scholar
  59. Deeg HJ, Shulman HM, Anderson JE et al. (2000) Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 95: 1188–1194PubMedGoogle Scholar
  60. Deeg HJ, Socie G (1998) Malignancies after hematopoietic stem cell trans- plantation: many questions, some answers. Blood 91: 1833–1844PubMedGoogle Scholar
  61. Deeg HJ, Storer B, SlatteryJTet al. (2002) Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unreleated donors in patients with myelodysplastic syndrome. Blood 100: 1201–1207PubMedGoogle Scholar
  62. Delforge M, Demuynck H, Vandenberghe P et aí. (1995) Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood 86: 3660–3667PubMedGoogle Scholar
  63. Delforge M, Demuynck H, Verhoef G et al. (1998) Patients with high-risk myelodysplastic syndrome can have polyclonal or clonal haemopoiesis in complete haematological remission. Br J Haematol 102: 486–494PubMedGoogle Scholar
  64. Demuynck H, Delforge M, Verhoef GEG, Zachee P, Vandenberghe P, van den Berg he H, Boogaerts MA (1996) Feasability of peripheral blood progenitor cell hyarvest and transplantation in patients with poor-risk myelodysplastic syndromes. Br J Haematol 92: 351–359PubMedGoogle Scholar
  65. Denzlinger C, Bowen D, Benz D, Gelly K, Brugger W, Kanz L (2000) Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplasic syndromes or secondary acute myeloid leukaemia. Br J Haematol 108: 93–95PubMedGoogle Scholar
  66. Di Gregorio F, Romeo MA, Pizzarelli G, Aiello G, Russo G (1997) An alternative to continuous subcutaneous infusion of desferrioxamine in thalassaemic patients.BrJ Haematol 98: 601–602Google Scholar
  67. Dong F, Brynes RK, Tidow N, Welte K, Löwenberg B, Touw IP (1995) Mutations in the gene for the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemia predended by severe congenital neutropenia. N Engl J Med 333: 487–493PubMedGoogle Scholar
  68. Emanuel PD (1999) Myelodysplasia and myeloproliferative disorders in childhood:an update. Br J Haematol 105: 852–863PubMedGoogle Scholar
  69. Emanuel PD, Shannon KM, Castleberry RP (1996) Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy. Mol Med Today 2: 468–475PubMedGoogle Scholar
  70. Emanuel PD, Snyder RC, Wiley T, Gopurala B, Castleberry RP (2000) Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. Blood 95: 639–645PubMedGoogle Scholar
  71. Estey EH, Kantarjian HM, O’Brien S et al. (1995) High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-T) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF ( G-CSF ). Cytokines Mol Ther 1: 21–28PubMedGoogle Scholar
  72. Estey EH, Kurzrock R, Talpaz M et al. (1991) Effects of low doses of recombinant human granulocyte-macrophage colony-stimulating factor ( GM-CSF) in patients with myelodysplastic syndromes. Br J Haematol 77: 291–295PubMedGoogle Scholar
  73. Estey EH, Thal! PF, Giles FJ et al. (2002) Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukaemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 99: 4343–4349PubMedGoogle Scholar
  74. Evans JS, Wennberg JE, McNeil BJ (1989) The influence of diagnostic radiography on the incidence of breast cancer and leukemia.N Engl J Med 315: 810–815Google Scholar
  75. Farrow A, Jacobs A, West RR (1989) Myelodysplasia, chemical exposure and other environmental factors. Leukemia 3: 33–35PubMedGoogle Scholar
  76. Feldman EJ, Seiter KP, Ahmed T, Baskind P, Arlin ZA (1995) Homoharringtonine in patients with myelodysplastic syndrome ( MDS) and MDS evolving to acute myeloid leukemia. Leukemia 10: 40–42Google Scholar
  77. Fenaux P, Beuscart R, Lai JL et al. (1988) Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol 6: 1417–1424PubMedGoogle Scholar
  78. Fenaux P, Lai JL, Jouet JP et aí. (1988) Aggressive chemotherapy in adult primary myelodysplastic syndromes. Blut 57: 297–302PubMedGoogle Scholar
  79. Fenaux P, Morel P, Rose C, Lai JL, Jouet JP, Bauters F (1991) Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 77: 497–501PubMedGoogle Scholar
  80. Ferrara F, Leoni F, Pinto A et al. (1999) Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes. Cancer 86: 2006–2013PubMedGoogle Scholar
  81. Francis GE, Wing MA, Miller EJ, Berney JJ, Wonke B, Hoffbrand AV (1983) Use of bone marrow culture in prediction of acute leukaemic transformation in pre-leukaemia. Lancet 1: 1409–1412PubMedGoogle Scholar
  82. Gajewski JL, Ho WG, Nimer SD, Hirji KF, Gekelman L, Jacobs AD, Champlin RE (1989) Efficacy of intensive chemotherapy for acute myelogenous leukaemia associated with a preleukaemic syndrome.) Clin Oncol 7: 1637–1645Google Scholar
  83. Gallagher A, Drley R, Padua RA (1997)The molecular basis of myelodysplastic syndromes (review). Haematologica 82: 191–204Google Scholar
  84. Ganser A (1988) Abnormalities of hematopoiesis in the acquired immunodeficiency syndrome. Blut 56: 49–53PubMedGoogle Scholar
  85. Ganser A (2003) Chemotherapy and stem cell transplantation for patients with myelodysplastic syndromes. Hematol 14 [Suppl 3]: 123–127Google Scholar
  86. Ganser A, Heil G, Seipelt G et al. (2000) Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk acute myeloid leukemia ( AML ). Ann Hematol 79: 30–35PubMedGoogle Scholar
  87. Ganser A, Hoelzer D (1992) Clinical course of myelodysplastic syndromes. Hematol Oncol Clin N Amer 6: 607–618Google Scholar
  88. Ganser A, Seipelt G, Lindemann A et al. (1990) Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes.Blood 76: 455–462Google Scholar
  89. Ganser A, Völkers B, Greher J etal. (1989) Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes–a phase ‘Atrial. Blood 73: 31–37PubMedGoogle Scholar
  90. Gardin C, Chaibi P, de Revel T et al. (1997) Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor ( G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Leukemia 11: 16–21Google Scholar
  91. Gattermann N, Aul C, Schneider W (1990) Two types of acquired idiopathic sideroblastic anaemia. Br J Haematol 74: 45–52PubMedGoogle Scholar
  92. Geissler RG, Schulte P, Ganser A (1997) Treatment with growth factors in myelodysplastic syndromes. Path Biol 45: 656–667Google Scholar
  93. Gerhartz HH, Marcus R, Delmar A et al. (1994) A randomized phase Il study of low-dose cytosine arabinoside (LD-araC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes ( MDS) with a high risk of developing leukemia. Leukemia 8: 16–23PubMedGoogle Scholar
  94. Germing U, Strupp C, Meckenstock G, Giagounidis A, Minning H, Aul C (1999) Klinik, Morphologie and Prognose chronischer myelomonozytärer Leukämien. Med Klinik 94: 467–472Google Scholar
  95. Gersuk GM, Beckham C, Loken MR et al. (1998) A role for tumour necrosis factor-alpha, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 103: 176–188PubMedGoogle Scholar
  96. Goasguen JE, Garand R, Bizet M et al. (1990) Prognostic factors of myelodysplastic syndromes–a simplified 3-D scoring system. Leuk Res 14: 255–260PubMedGoogle Scholar
  97. Golub TR, Barker GF, Lovett M, Gilliland G (1994) Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77: 307–316PubMedGoogle Scholar
  98. Gordon MS, Nemunaitis J, Hoffman R et al. (1995) A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 85: 3066–3076PubMedGoogle Scholar
  99. Gore SD, Burke PJ (1995) Long-term survival of subsets of patients with advanced myelodysplastic syndromes (MDS) treated with intensive chemotherapy (abstract). Blood 86 [Suppl 1]: 339aGoogle Scholar
  100. Greenberg P, Cox C, LeBeau MM et al. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2077–2088Google Scholar
  101. Greenberg P, Taylor K, Larson R et al. (1993) Phase Ill randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndromes (MDS). Blood 82 [Suppl 11: 196aGoogle Scholar
  102. Groet J, McElwaine S, Spinelli M et al. (2003) Acquired mutations in GATA1 in neonates with Down’s syndrome with transient myeloid disorder. Lancet 361: 1617–1620PubMedGoogle Scholar
  103. Gupta P, LeRoy SC, Luikart SD, Bateman A, Morrison VA (1999) Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leuk Res 23: 953–959PubMedGoogle Scholar
  104. Haas OA, Gadner H (1996) Pathogenesis, biology, and management of myelodysplastic syndromes in children. Semin Hematol 33: 225235Google Scholar
  105. Hamblin T (1992) Immunologic abnormalities in myelodysplastic syndromes. Hematol Oncol Clin N Amer 6: 571–586Google Scholar
  106. Harris NL, Jaffe ES, Diebold J et al. (1999) World Health Organization classification ofneoplastic diseases of the hematopoietic and lymphoid tissues:report of the clinical advisory committee meeting -Airlie House, Virginia, November 1997. J Clin Oncol 17: 3835–3849PubMedGoogle Scholar
  107. Hasle H (1994) Myelodysplastic syndromes in childhood–classification, epidemiology, and treatment. Leuk Lymphoma 13: 11–26PubMedGoogle Scholar
  108. Hasle H, Kerndrup G, Jacobson BB (1995) Childhood myelodysplastic syndrome in Denmark:incidence and predisposing conditions. Leukemia 9: 1569–1572PubMedGoogle Scholar
  109. Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G. Head DR (2003) A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 17: 277282Google Scholar
  110. Hellström-Lindberg E (1995) Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 89: 67–71PubMedGoogle Scholar
  111. Hellström-Lindberg E, Kanter-Lewensohn L, Nichol J, Ost A (1999) Spontaneous and cytokine-induced thrombocytopenia in myelodysplastic syndromes:serum thrombopoietin levels and bone marrow morphology. Scandinavian MDS Group, Sweden and Norway. Br J Haematol 105: 966–973PubMedGoogle Scholar
  112. Hellström-Lindberg E, Kanter-Lewensohn L, Ost A (1997b) Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk Res 21: 415–425PubMedGoogle Scholar
  113. Hellström-Lindberg E, Negrin R, Stein R et al. (1997a) Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes:proposal for a predictive model.BrJ Haematol 99: 344–351PubMedGoogle Scholar
  114. Hellström-Lindberg E, Robert KH, Gahrton G et aí. (1992) A predictive model for the clinical response to low dose ara-C: a study of 102 patients with myelodysplastic syndromes or acute leukemia. Br J Haematol 81: 503–511PubMedGoogle Scholar
  115. Hellström-Lindbergh E, Gulbrandsen N, Lindberg G et al. (2003) A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 120: 1037–1046Google Scholar
  116. Herman JG, Jen J, Merlo A, Baylin SB (1996) Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4b Cancer Res 56: 722–727Google Scholar
  117. Hofmann WK, de Vos S, Komor M, Hoelzer D, Wachsman W, Koeffler HP (2003) Characterization of gene expression ofCD34+cells from normal and mylodysplastic bone marrow. Blood 100: 3553–3560Google Scholar
  118. Horiike S, Misawa S, Nakai H et al. (1994) N-Ras muation and karyotype evolution are closely associated with leukemic transformation in myelodysplastic syndrome. Leukemia 8: 1331–1336PubMedGoogle Scholar
  119. Horiike S, Taniwaki M, Misawa S, Abe T (1988) Chromosome abnormalities and karyotypic evolution in 83 patients with myelodysplastic syndrome and predictive value for prognosis. Cancer 62: 1129–1138PubMedGoogle Scholar
  120. Hoyle CF, De Bastos M, Wheatley K et al. (1989) AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: Results from the MRC’s 9th AML trial. Br J Haematol 72: 45–53PubMedGoogle Scholar
  121. Imashuku S, Hibi S, Nakajima F et al. (1994) A review of 125 cases to determine the risk of myelodysplasia and leukemia in pediatric neutro-penic patients after treatment with recombinant human granulocyte colony-stimulating factor. Blood 84: 2380–2381PubMedGoogle Scholar
  122. Iselius L, Jacobs P, Morton N (1990) Leukaemia and transient leukaemia in Down Syndrome. Hum Genet 85: 477–485PubMedGoogle Scholar
  123. Janasova A, Neuwirtova R, Cermak J, Vozobulova V, Mocikova K, Siskova M, Hochova I (1998) Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 100: 304–309Google Scholar
  124. Janssen JWG, Buschle M, Layton M et al. (1989) Clonal analysis of myelodysplastic syndromes: evidence of multipotential stem cell origin. Blood 73: 248–254PubMedGoogle Scholar
  125. Jensen PD, Heickendorff L, Pedersen B et al. (1996) The effect of iron chelation on haemopoisis in MDS patients with transfusional iron overload. Br J Haematol 94: 288–299PubMedGoogle Scholar
  126. Josting A, Wiedenmann S, Franklin J et al. (2003) Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin’s disease: a report from the German Hodgkin’s Lymphoma Study Group.) Clin Oncol (Epub ahead of print)Google Scholar
  127. Kakazu N, Taniwaki M, Horiike S et al. (1999) Combined spectral karyotyping and DAPI banding analysis of chromosome abnormalities in myelodysplastic syndrome.Genes Chromosomes Cancer 26: 336–345Google Scholar
  128. Kalra R, Dale D, Freedman M et al. (1995) Monosomy 7 and activating RAS mutations accompany malignant transformation in patients with congenital neutropenia. Blood 86: 4579–4586PubMedGoogle Scholar
  129. Kampmeier P, Anastasi J, Vardiman JW (1992) Issues in the pathology of the myelodysplastic syndromes. Hematol Oncol Clin N Amer 6: 501–522Google Scholar
  130. Kane EV, Roman E, Cartwright R, Parker 1, Morgan G (1999) Tobacco and the risk of acute leukaemia in adults. Br) Cancer 81: 1228–1233Google Scholar
  131. Keating MJ, Mc Credie KB, Benjamin RS, Bodey GP, Zander A, Smith TL, Freireich EJ (1981) Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone ( ROAP ). Blood 58: 584–591PubMedGoogle Scholar
  132. Knauf WU, Berdel WE, Ho AD et al. (1994) Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia. Leuk Lymph 12: 421–425Google Scholar
  133. Knave B (1992) Electric and magnetic fields and health outcomes: an overview. Scand 1 Work Environ Health 20: 78–89Google Scholar
  134. Kochenderfer JN, Kobayashi S, Wieder ED, Su C, Molldrem JJ (2002) Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 100: 639–645Google Scholar
  135. Koeffler HP, Heitjan D, Mertelsmann R. (1988) Randomized study of 13-cis retinoic acid versus placebo in the myelodysplastic disorders. Blood 71: 703–708PubMedGoogle Scholar
  136. Kojima S, Ohara A, Tsuchida M et al. (2002) Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukaemia after immunosuppressive therapy in children. Blood 100: 786–790PubMedGoogle Scholar
  137. Kornblith AB, Herndan JE, Silverman LR et al. (2002) Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.) Clin Oncol 20: 2441–2452Google Scholar
  138. Kurahashi H, Hara), Yumura-Yagi K et al. (1991) Monoclonal nature of transient abnormal myelopoiesis in Down’s syndrome. Blood 77: 22622263Google Scholar
  139. Lai H, Preudhomme C, Zandecki M et al. (1995) Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and high incidence of p53 mutations. Leukemia 9: 370–381PubMedGoogle Scholar
  140. Lai JL, Fenaux P (1997) Cytogenetics of myelodysplastic syndromes. Path Biol 45: 550–555Google Scholar
  141. Lambertenghi-Deliliers G, Orazi A, Luksch R et al. (1991) Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinicopathological entity. Br J Haematol 78: 161–166PubMedGoogle Scholar
  142. Lange BJ, Kobrinsky N, Barnard DR et al. (1998) Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndromes;Children’s Cancer Group Studies 2861 and 2891. Blood 91: 608–615PubMedGoogle Scholar
  143. Laporte JP, Isnard F, Lesage S et al. (1993) Autologous bone marrow transplantation with marrow purged by mafosfamide in seven patients with myelodysplastic syndromes in transformation (AML-MDS): a pilot study. Leukemia 7: 2030–2033PubMedGoogle Scholar
  144. Linman JW, Bagby GC (1978) The preleukemic syndrome (hematopoietic dysplasia). Cancer 42: 854–864PubMedGoogle Scholar
  145. List AF, Brasfield F, Heaton R, Glinsmann-Gibson B, Crook L, Taetle R, Capizzi R (1997) Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 90: 3364–3369PubMedGoogle Scholar
  146. Locatelli F, Niemeyer C, Angelucci E et al. (1997) Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood:a report from the European Working Group on Myelodysplastic Syndrome in Childhood.) Clin Oncol 15: 566–573Google Scholar
  147. Luna-Fineman S, Shannon KM, Atwater SK et al. (1999) Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood 93: 459–466PubMedGoogle Scholar
  148. Luna-Fineman S, Shannon KM, Lange BJ (1995) Childhood monosomy 7: epidemiology, biology and mechanistic implications. Blood 85: 19851999Google Scholar
  149. Mangi MH, Mufti GJ (1992) Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies. Blood 79: 198–205PubMedGoogle Scholar
  150. Martiat P, Ferrant A, MichauxJL, Sokal G (1988) Intensive chemotherapy for acute non-lymphoblastic leukemia after primary myelodysplastic syndrome. Haematol Oncol 6: 299–305Google Scholar
  151. Matsushima T, Handa H, Yokohama A et al. (2003) Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood 101: 3386–3390PubMedGoogle Scholar
  152. Mattijssen V, Schattenberg A, Schaap N, Preijers F, De Witte T (1997) Outcome of allogeneic bone marrow transplantation with lymphocyte-depleted marrow grafts in adult patients with myelodysplastic syndromes. Bone MarrowTranspl 19: 791–794Google Scholar
  153. Maynadie M, Picard F, Husson B et al. (2002) Immunophenotypic clustering of myelodysplastic syndromes. Blood 100: 2349–2356PubMedGoogle Scholar
  154. Mertelsmann R, Thaler HT, To L et al. (1980) Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood 56: 773–781PubMedGoogle Scholar
  155. Metayer C, Curtis RE, Vose J et al. (2003) Myelodysplastic syndrome and acute myeloid leukaemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 101: 2015–2023PubMedGoogle Scholar
  156. Micallef INM, Lillington DM, Apostolidis J et al. (2000) Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies.) Clin Oncol 18: 947–955Google Scholar
  157. Michels SD, McKenna RW, Arthur DC et al. (1985) Therapy-related acute myeloid leukemia and myelodysplastic syndrome:a clinical and morphological study of 65 cases. Blood 65: 1365–1372Google Scholar
  158. Michels SD, Saumur J, Arthur DC, Robison LL, Brunning RD (1989) Refractory anemia with excess of blasts in transformation: hematological and clinical study of 52 patients. Cancer 64: 2340–2346PubMedGoogle Scholar
  159. Miller KB, Kyungman K, Morrison FS et al.(1992)The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes:a phase III intergroup study. Ann Hematol 65: 162–168Google Scholar
  160. Milligan DW, Ruiz De Elvira MC, Kolb HJ et al. (1999) Secondary leukaemia and myelodysplasia after autografting for lymphoma:results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br J Haematol 106: 1020–1026Google Scholar
  161. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ (1997) Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 99: 699–705PubMedGoogle Scholar
  162. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett Al (1998) Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lym-phocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 102: 1314–1322PubMedGoogle Scholar
  163. Molldrem JJ, Leifer E, Bahceci E, et al (2002) Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 137: 156–163PubMedGoogle Scholar
  164. Morel P, Hebbar M, Lai JL et al. (1993) Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 7: 1315–1323PubMedGoogle Scholar
  165. Morosetti R, Koeffler HP (1996) Differentiation therapy in myelodysplastic syndromes. Semin Hematol 3: 236–245Google Scholar
  166. Mufti GJ, StevensJR, Oscier DG, Hamblin TJ, Machin D (1985) Myelodysplastic syndromes. A scoring system with prognostic significance. Br J Haematol 59: 425–433Google Scholar
  167. Najean Y, Pecking A (1979) Refractory anemia with excess of blast cells: prognostic factors and effect of treatment with androgens or cytosine arabinoside. Results of a prospective trial in 58 patients. Cancer 44: 1976–1982PubMedGoogle Scholar
  168. Negrin R, Haeubre DH, Nagler A et al. (1989) Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor.A phase I/II trial. Ann Intern Med 110: 976–984PubMedGoogle Scholar
  169. Negrin RS, Haeuber DH, Nagler A et al. (1990) Maintenance therapy of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 76: 36–43PubMedGoogle Scholar
  170. Negrin RS, Stein R, Vardiman J et al. (1993) Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 82: 737–743PubMedGoogle Scholar
  171. NeubauerA, Greenberg P, Negrin R, Ginzton N, Liu E (1994) Mutations in the RAS proto-oncogenes in patients with myelodysplastic syndromes. Leukemia 8: 638–641Google Scholar
  172. Nevill TJ, Fung HC, Shepherd JD et al. (1998) Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 92: 1910–1917PubMedGoogle Scholar
  173. Niemeyer C, Aricò M, Basso G et al. (1997) Chronic myelomonocytic leukemia in childhood:a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood ( EWOGMDS ). Blood 89: 3534–3543PubMedGoogle Scholar
  174. Niemeyer CM, Fenu S, Hasle H, Mann G, Stary J, van Wering ER (1998) Differentiating juvenile myelomonocytic leukemia from infectious disease. Blood 91: 365–367Google Scholar
  175. Nisse C, Lorthois C, Dorp V, Eloy E, Haguenoer JM, Fenaux P (1995) Exposure to occupational and environmental factor in myelodysplastic syndromes. Preliminary results of a case-control study. Leukemia 9: 693699Google Scholar
  176. Nucifora G, Rowley JD (1995) AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 86: 1–14PubMedGoogle Scholar
  177. O’Donnell MR, Long GD, Parker PM et al. (1995) Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia.J Clin Oncol 13: 2973–2979Google Scholar
  178. Ogata K, Nakamura K, Yokose N et al. (2002) Clinical significance of phenotypic features of blast cells in patients with myelodysplastic syndrome. Blood 100: 3887–3896PubMedGoogle Scholar
  179. Oguma S, Yoshida Y, Unicho H et al. (1995) Clinical characteristics on Japanese patients with primary myelodysplastic syndromes: a cooperative study based on 838 cases. Leuk Res 19: 219–225PubMedGoogle Scholar
  180. Ohno R, Naoe T, Hirano M et al. (1993) Treatment of myelodysplastic syndromes with all-trans retinoic acid. Leukemia Study Group of the Ministry of Health and Welfare. Blood 81: 1152–1154Google Scholar
  181. Olson JH, Nielson A, Schulgen G (1993) Residence near high voltage facilities and risk of cancer in children. Br Med J 307: 891–895Google Scholar
  182. Ooi J, IsekiT, Takahashi Set al. (2003) Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. Blood 101: 4711–4713Google Scholar
  183. Oosterveld M, Suciu S, Verhoef G et al. (2003) The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia 17: 859–868PubMedGoogle Scholar
  184. Ossenkoppele GJ, Verhoef GEG, Verfoef GEG et al. (1995) Randomized phase lI study on the value of G-CSF (filgrastim) in combination with standard induction chemotherapy in myelodysplastic syndromes (MDS) (abstract). Blood 86 [Suppl 11: 338aGoogle Scholar
  185. Padua RA, Guinn BA, Al-Sabah Al et aí.(1998) RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasia: a 10-year follow-up. Leukemia 12: 887–892Google Scholar
  186. Park DJ, Koeffler HP (1996) Therapy-related myelodysplastic syndromes. Semin Hematol 33: 256–273PubMedGoogle Scholar
  187. Parker JE, Mufti GJ (1998) Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes (review). Br J Haematol 101: 220–230PubMedGoogle Scholar
  188. Passmore Si, Hann LM, Stiller CA et al. (1995) Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system. Blood 85: 1742–1750Google Scholar
  189. Pedersen-Bjergaard J, Philip P (1991) Balanced translocations involving chromosome bands 11g23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II (letter). Blood 78: 11471148Google Scholar
  190. Pomeroy C, Oken MM, Rydell RE, Filice GA (1991) Infection in the myelodysplastic syndromes. Am J Med 90: 338–344PubMedGoogle Scholar
  191. Prchal JT, Throckmorton DW, Carroll AJ, Fuson EW, Gams RA, Prchal JF (1978) A common progenitor for human myeloid and lymphoid cells. Nature 274: 590–591PubMedGoogle Scholar
  192. Pruneri G, Bertolini F, Soligo D et al. (1999) Angiogenesis in myelodysplastic syndromes. Br J Cancer 81: 1398–1401PubMedGoogle Scholar
  193. Quesnel B, Guillerm G, Vereecque R et al. (1998) Methylation of the p15INK4b gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91: 2985–2990PubMedGoogle Scholar
  194. Radlund A, Thiede T, Hansen S, Carlsson M, Enquist L (1995) Incidence of myelodysplastic syndromes in a Swedish population. Eur J Haematol 54: 153–156PubMedGoogle Scholar
  195. Rajapaksa R, Ginzton N, Rott LS, Greenberg PL (1996) Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 88: 4275–4284PubMedGoogle Scholar
  196. Raza A, Gezer S, Gregory SA et al. (1996) Anti-cytokine therapyproduces responses in patients with myelodysplastic syndromes ( MDS ). Blood 88: 580aGoogle Scholar
  197. Raza A, Gezer S, Mundle Set al. (1995) Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86: 268–276PubMedGoogle Scholar
  198. Raza A, Meyer P, Dutt D et al. (2001) Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98: 958–965PubMedGoogle Scholar
  199. Raza A, Qwawi H, Lisak L et al. (2000) Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamathasone. Blood 95: 1580–1587PubMedGoogle Scholar
  200. Rhoads CP, Barker WH (1938) Refractory anemia: analysis of one-hundred cases.J Am Med Assoc 110: 794–796Google Scholar
  201. Ribera JM, Cervantes F, Rozman C (1987) A multivariate Analysis of prognostic factors in chronic myelomonocytic leukaemia according to the FAB criteria. Br J Haematol 65: 307–311PubMedGoogle Scholar
  202. Richardson S, Zittoun R, Bastuji-Garin S et al. (1992) Occupational risk factors for acute leukemia: a case-control study. Int J Epidemiol 21: 1063–1073PubMedGoogle Scholar
  203. Rinsky RA, Young RJ, Smith AB (1991) Leukemia in benzene workers. Am J Ind Med 2: 217–245Google Scholar
  204. Rowinsky EK, Conley BA, Jones RJ et al. (1992) Hexamethylene bisacetamide in myelodysplastic syndrome: Effect of five-day exposure to maximal therapeutic concentrations. Leukemia 6: 526–534PubMedGoogle Scholar
  205. Ruutu T, Hänninen A, Järventie G et al. (1994) Intensive treatment of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia subsequent to MDS with idarubicin and cytarabine (abstract). Br J Haematol 87 [Suppl 11: 19Google Scholar
  206. Sandberg AA (1990) The chromosomes in human cancer and leukaemia, 2nd edn. Elsevier Science, New YorkGoogle Scholar
  207. Sanz GF, Sanz MA (1992) Prognostic factors in myelodysplastic syndromes. Leuk Res 16: 77–86PubMedGoogle Scholar
  208. Sanz GF, Sanz MA, VallespiTet al. (1989) Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes. A multivariate analysis of prognostic factors in 370 patients. Blood 74: 395–408PubMedGoogle Scholar
  209. Sashida G, Ohyashiki JH, Nakajima A et al. (2003) Telomere dynamics in myelodysplastic syndrome determined by telomere measurement of marrow metaphases. Clin Cancer Res 9: 1489–1496PubMedGoogle Scholar
  210. Saunthararajah Y, Nakamura R, Nam JM et al. (2002) HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndromes. Blood 100: 1570–1574PubMedGoogle Scholar
  211. SaunthararajahY, Nakamura R, Wesley R, Barrett Ai (2003) A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndromes. Blood 102 (im Druck)Google Scholar
  212. Savitz DA, Calle EE (1987) Leukemia and occupational exposure to electromagnetic fields: review of epidemiologic surveys. J Occup Med 29: 47–51PubMedGoogle Scholar
  213. Seymor JF, Estey EH (1995) The contribution of Auer rods to the classification and prognosis of myelodysplastic syndromes. Leuk Lymphoma 17: 9–85Google Scholar
  214. Shannon KM, O’Connell P, Martin GA et aí. (1994) Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 330: 597–601PubMedGoogle Scholar
  215. Shepherd PCA, Ganesan TS, Galton DAG (1987) Haematological classification of the chronic myeloid leukaemias. Bailliere’s Clinical Haematology 1: 887–906Google Scholar
  216. Shore RE, Martin JG, Pannette B (1993) Ethylene oxide:an assessment of the epidemiological evidence on carcinogenicity. Br J Ind Med 50: 971–997PubMedGoogle Scholar
  217. Shuster MW, Larson RA, Thompson JA, Coiffier B, Bennett J, Dugan M (1995) Randomized phase II study of recombinant human granulocyte-macrophage colony-stimulating factor (rGM-CSF) in patients with neutropenia secondary to myelodysplastic syndromes. Blood 86 [Suppl 1]: 338aGoogle Scholar
  218. Sierra J, Carreras E, Rozman C, Champlin R, Rowlings P, Horowitz M (2002) Bone marrow transplantation for myelodysplasia: the IBMTR data. Leuk Res 21 [Suppl 1]: 551Google Scholar
  219. Silverman LR, Davis RB, Holland JF et al. (1989) 5-Azacytidine (AZ) as a low-dose continuous infusion is an effective therapy of patients with myelodysplastic syndromes ( MDS ). Blood 73: 263–270Google Scholar
  220. Silverman LR, Demakos EP, Peterson BL et aí. (2002) Randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B.1 Clin Oncol 20: 2429–2440Google Scholar
  221. Smith PG (1977) Leukemia and other cancers following radiation treatment of pelvic disease. Cancer 39: 1901–1905PubMedGoogle Scholar
  222. Smith PG, Douglas A (1976) Mortality of workers at the Sellafield plant of British Nuclear fuels. Br Med J 293: 845–854Google Scholar
  223. Smith RE, Bryant J, DeCillis A, Anderson S, National Surgical Adjuvant Breast and Bowel Project Experience (2003) Acute myeloid leukaemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide ad- juvant therapy for operable breast cancer:the National Surgical Adju- vant Breast and Bowel Project Experience.J Clin Oncol 21: 1195–1204Google Scholar
  224. Solé F, Espinet B, Sanz GF et al. (2000) Incidence, characterization and prog- nostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes.BrJ Haematol 108: 346–356Google Scholar
  225. Steensma DR Dispenzieri A, Moore SB, Schroeder G, Tefferi A (2003) Antithy- mocyte globulin has limited efficacy and substantial toxicity in unse-lected anemic patients with myelodysplastic syndrome. Blood 101: 2156–2158PubMedGoogle Scholar
  226. Steinmetz HT, Staib P, Glasmacher A, Neufang A, Katay I, Diehl V, Dias Wickramanayake P (1996) Phase II study of idarubicin, fludarabine, Ara-C, and G-CSF (Ida-FLAG) for treatment of refractory, relapsed and secondary acute myeloid leukemia (abstract).Br1 Haematol 93 [Suppl] 21: 219Google Scholar
  227. Stephenson J, Mufti GJ, Yoshida Y (1993) Myelodysplastic syndromes:from morphology to molecular biology. Part II. The molecular genetics of myelodysplasia. Int J Hematol 57: 99–112PubMedGoogle Scholar
  228. Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N (2002) Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 16: 1–6PubMedGoogle Scholar
  229. Sutton L, Chastang C, Ribaud P et al. (1996) Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantatio: a long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood 88: 358–365PubMedGoogle Scholar
  230. Takagi S, Tanaka O, Origasa H, Miura Y (1999) Prognostic significance of magnetic resonance imaging of femoral marrow in patients with myelodysplastic syndromes.J Clin Oncol 17: 277–283Google Scholar
  231. Tartaglia M, Niemeyer CM, Fragale A (2003) Somatic mutations in PTPN11 in juvenile myelomonocytic leukaemia, myelodysplastic syndromes and acute myeloid leukaemia. Nat Genet 34: 148–150PubMedGoogle Scholar
  232. Tessema M, Langer F, Dingemann J, Ganser A, Kreipe H, Lehmann U (2003) Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulator gene in chronic myelomonocytic leukaemia ( CMML ). Leukemia 17: 910–918PubMedGoogle Scholar
  233. Third MIC Cooperative Group (1988) Recommendations for a morphologic, immunologic, and cytogenetic (MIC) working classification of the primary and therapy-related myelodysplastic disorders.Cancer Genet Cytogenet 32: 1–10Google Scholar
  234. Tien HF, Wang CH, Chuang SM et al. (1994) Cytogenetic studies, ras mutation, and clinical characteristics in primary myelodysplastic syndrome. A study on 68 Chinese patients in Taiwan. Cancer Genet Cytogenet 74: 40–49PubMedGoogle Scholar
  235. Tricot G, Boogaerts MA, De Wolf-Peeters C, Van Den Berghe H, Verwilghen RL (1985) The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations. Br J Haematol 59: 659–670PubMedGoogle Scholar
  236. Tuzuner N, Cox C, Rowe JM, Watrous D, Bennett JM (1995) Hyypocellular myelodysplastic syndromes (MDS): new proposals. Br J Haematol 91: 612–617PubMedGoogle Scholar
  237. Vadhan-Raj S, Kellagher MJ, Keating M et al. (1988) Phase I study of recombinant human granulocyte-macrophage colony stimulating factor in patients with myelodysplastic syndrome. N Engl J Med 317: 1545–1552Google Scholar
  238. Van den Berghe H, Vermaelen K, Mecucci C, Barbieri D, Tricot G (1985) The 5q- anomaly. Cancer Genet Cytogenet 17: 189–255PubMedGoogle Scholar
  239. van Kamp H, Fibbe WE, Jansen RPM et al. (1992) Clonal involvement of granulocytes and monocytes, but not of T and B lymphocytes and natural killer cells in patients with myelodysplasia: analysis by X-linked restriction fragment length polymorphisms and polymerase chain reaction of the phosphoglycerate kinase gene. Blood: 17741780Google Scholar
  240. Verbeek W, Wörmann B, Koch P et al. (1997) S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes. Ann Hematol 74: 205–208PubMedGoogle Scholar
  241. Verburgh A, Achten R, Maes B et al. (2003) Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes.J Clin Oncol 21: 273–282Google Scholar
  242. Verhoef GE, De Schouwer P, Ceuppens JL, Van Damme J, Goossens W, Boogaerts MA (1992) Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 6: 1268–1272PubMedGoogle Scholar
  243. Vigliani EC (1976) Leukemia associated with benzene exposure. Ann NY Acad Sci 271: 143–151PubMedGoogle Scholar
  244. Wattel E, De Botton S, Lai LJ, Preudhomme C, Lepelley P, Bauters F, Fenaux P (1997b) Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders. Br J Haematol 98: 983–991PubMedGoogle Scholar
  245. Wattel E, Guerci A, Hecquet B et al. (1996) A randomized trial of hydroxyurea versus VP 16 in adult chronic myelomonocytic leukemia. Blood 88: 2480–2487PubMedGoogle Scholar
  246. Wattel E, Preudhomme C, Hecquet B et al. (1994) p53 mutations are associated with resistance to chemotherapy and short survival in hematological malignancies. Blood 84: 3148–3157Google Scholar
  247. Wattel E, Solary E, Caillot D et al. (1995) Intensive chemotherapy (CT) with or without quinine followed by autologous BMT in myelodysplastic syndromes (MDS) and secondary leukemia (SL). Preliminary results of a randomized trial (abstract). Blood 86 [Suppl 1): 804aGoogle Scholar
  248. Wattel E, Solary E, Caillot et al. (1997a) Autologous bone marrow (ABMT) or peripheral blood stem cell (ABSCT) transplantation after intensive chemotherapy in myelodysplastic syndromes (MDS) (abstract). Leuk Res21 (Suppl 1 ): S52Google Scholar
  249. Wells DA, Benesch M, Loken MR et al. (2003) Myeloid and monocytic dyspoiesis determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 102: 394–403PubMedGoogle Scholar
  250. West R, Stafford DA, Farrow A, Jacobs A (1995) Occupational and environmental exposures and myelodysplasia. Leuk Res 19: 127–139PubMedGoogle Scholar
  251. White AD, Culligan DJ, Hoy TG, Jacobs A (1992) Extended cytogenetic follow-up of patients with myelodysplastic syndrome. Br J Haematol 81: 499–502PubMedGoogle Scholar
  252. Wijermans PW, Krulder JWM, Huijgens PC, Neve P (1997) Continuous infusion of low-dose 5-Aza-2’-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 11: 1–5PubMedGoogle Scholar
  253. Wijermans PW, Lübbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2000) Low-dose 5-aza-2’-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase Il study in elderly patients.J Clin Oncol 18: 956–962Google Scholar
  254. Wilkinson GS, Tietjen GL, Wiggs LD (1987) Mortality among plutonium and other radiation workers at a plutonium weapons facility. Am J Epidemiol 125: 231–250PubMedGoogle Scholar
  255. Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier DG (1994) Establishing the incidence of myelodysplastic syndromes. Br J Haematol 87: 743–745PubMedGoogle Scholar
  256. Wing S, Shy CM, Wood JL (1991) Mortality among workers at Oak Ridge National Laboratory.J Am Med Ass 265: 1397–1402Google Scholar
  257. Worsley A, Oscier DG, Stevens J et al. (1988) Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival. Br J Haematol 68: 17–21PubMedGoogle Scholar
  258. Yakoub-Agha I, de La Salmonière P, Ribaud Petal. (2000) Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients–report of the French Society of Bone Marrow Transplantation.) Clin Oncol 18: 963–971Google Scholar
  259. Zagonel V, Lo Re G, Marotta G et al. (1993) 5-Aza-2’-doxycytidine ( Decitabine) induces trinlineage response in unfavorable myelodysplastic syndromes. Leukemia 7: 30–35PubMedGoogle Scholar
  260. Zorat F, Shetty V, Dutt D et al. (2001) The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes.BrJ Haematol 115: 881–894Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • A. Ganser

There are no affiliations available

Personalised recommendations